^
    1d
    CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov)
    P2, N=80, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 positive
    |
    zeprumetostat (SHR-2554) • Lunsumio (mosunetuzumab-axgb)
    12d
    Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    zeprumetostat (SHR-2554) • AiRuiLi (adebrelimab)
    1m
    SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    cytarabine • azacitidine • cyclophosphamide • zeprumetostat (SHR-2554)
    1m
    SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    cytarabine • azacitidine • cyclophosphamide • zeprumetostat (SHR-2554)
    1m
    CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    CD20 positive
    |
    zeprumetostat (SHR-2554) • Lunsumio (mosunetuzumab-axgb)
    2ms
    MA-GC-II-022: PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer (clinicaltrials.gov)
    P2, N=78, Recruiting, The First Affiliated Hospital of Zhengzhou University | N=36 --> 78
    Enrollment change
    |
    AiTan (rivoceranib) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554)
    3ms
    Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, Ruijin Hospital
    New P1/2 trial
    |
    azacitidine • decitabine • Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    3ms
    Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Fudan University | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial primary completion date
    |
    zeprumetostat (SHR-2554) • AiSuDa (ivarmacitinib)
    3ms
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • risvutatug rezetecan (GSK5764227)
    4ms
    Clinical Study on the Efficacy and Safety of Zeprumetostat, Azacitidine Combined with Lipo-MIT in Relapsed/Refractory Peripheral T-Cell Lymphoma. (ChiCTR2600116686)
    P2, N=26, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • zeprumetostat (SHR-2554) • Duoenda (mitoxantrone liposomal)
    4ms
    Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL (clinicaltrials.gov)
    P2, N=26, Recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • zeprumetostat (SHR-2554) • Duoenda (mitoxantrone liposomal)
    5ms
    SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    zeprumetostat (SHR-2554)